Zai Lab Ltd — SEC Form D Filing
Zai Lab Ltd filed an SEC Form D on November 9, 2026, reporting $249.93M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 9, 2026
- Amount reported
- $249.93M
- Round stage
- Series B+
- Industry
- Biotechnology
- Website
- https://www.zailaboratory.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: CAYMAN ISLANDS
Problem
Patients suffer from severe medical conditions with limited treatment options and significant unmet medical needs across oncology, immunology, neuroscience, and infectious diseases.
Solution
Zai Lab discovers, develops, and commercializes targeted therapies—including antibody-drug conjugates and bispecific antibodies—while in-licensing late-stage therapeutic assets through strategic partnerships to advance treatments through clinical trials to market.
Why now
Rapid expansion of precision oncology and cross-border clinical development allows biopharmas to bridge global research and accelerate market access across the US and Asia.
Verdict
Investors backed Zai Lab to arbitrage regional clinical trial costs and capture Greater China commercial rights amid local regulatory liberalization. They implicitly wagered that Western biotechs would perpetually outsource regional commercialization rather than establish direct Asian footprints. This cleared because execution speed in regional licensing de-risked clinical asset validation, not because internal discovery capabilities offered superior therapeutic novelty. Upside was inherently capped by heavy royalty stack friction and growing geopolitical exposure on cross-border intellectual property transfers.
Source: SEC EDGAR Form D filing